Unicycive Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 19, 2026, reports the final results of the Annual Meeting of Stockholders held on June 19, 2025. Unicycive Therapeutics, Inc. is a Delaware corporation listed on the Nasdaq Capital Market under the symbol UNCY. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 14,964,159 shares were represented at the meeting, constituting a quorum. The following matters were approved:
- Proposal 1 (Election of Directors): All three nominees were elected to serve until the 2027 Annual Meeting.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Grassi & Co. CPAs, P.C. as the independent registered public accounting firm for the fiscal year ended December 31, 2026.
| Director Nominee | For | Withhold | Broker Non-Votes |
|---|---|---|---|
| Dr. Shalabh Gupta | 8,131,958 | 173,587 | 6,658,614 |
| Dr. Sandeep Laumas | 7,696,050 | 609,525 | 6,658,584 |
| D. Sarawati Kenkare-Mitra | 7,510,434 | 795,108 | 6,658,617 |
| Proposal 2: Auditor Ratification | For | Against | Abstain | Broker Non-Vote |
|---|---|---|---|---|
| Grassi & Co. CPAs, P.C. | 14,667,242 | 286,958 | 9,928 | 31 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the discrepancy between the report date (June 19, 2026) and the meeting date (June 19, 2025) as stated in the text.
- Confirm the high volume of broker non-votes (approx. 6.6 million shares) for the director elections, which may indicate significant institutional holdings.
- Review the Definitive Proxy Statement filed on April 30, 2026, for detailed biographical information on the elected directors.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.